A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 13 Apr 2018 Planned number of patients changed from 120 to 100.
- 13 Apr 2018 Planned End Date changed from 7 Dec 2020 to 14 Mar 2021.
- 24 Oct 2017 Status changed from not yet recruiting to recruiting.